Federal Contractor Profile
Crestone, INC.
$60M obligated·5 awards·2 agencies·3 NAICS
Federal Contracts
Showing award actions 1–26 of 26 funded award actions, most recent first.
- Contracts with positive obligations
- 5
- Funded award actions shown
- 26
- Obligations shown
- $60M
- Awarding agencies
- 2
This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.
Award data as of August 20, 2026. Source: USAspending federal award records.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Jun 16, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00056 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $1.4M |
| Apr 23, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00020 | 541715 | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | $1.6M |
| Jan 7, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00020 | 541715 | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | $2.0M |
| Jun 25, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00056 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $3.3M |
| Dec 3, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00056 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $573K |
| Nov 26, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00020 | 541715 | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | $1.6M |
| Aug 7, 2024 | Department of Veterans AffairsNETWORK CONTRACT OFFICE 19 (36C259) | 36C25924P1167 | 541714 | SYNTHESIS AND TESTING LABORATORY SERVICES FOR RESEARCH | $99K |
| Aug 1, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00056 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $4.6M |
| Jun 7, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00020 | 541715 | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | $971K |
| Aug 31, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00020 | 541715 | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | $2.7M |
| Aug 17, 2023 | Department of Veterans AffairsNETWORK CONTRACT OFFICE 19 (36C259) | 36C25923P1093 | 541714 | SYNTHESIS AND TESTING OF NOVEL ANTIBIOTIC CHEMICAL COMPOUNDS FOR ROCKY MOUNTAIN REGIONAL VA MEDICAL CENTER RESEARCH DEPARTMENT | $102K |
| Jul 20, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00056 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $3.5M |
| Sep 29, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00020 | 541715 | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | $141K |
| Sep 20, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00056 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $4.5M |
| Sep 20, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00020 | 541715 | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | $5.8M |
| Dec 10, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00020 | 541715 | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | $3.7M |
| Dec 4, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00056 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $851K |
| Aug 12, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00056 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $9.8M |
| Jun 29, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00020 | 541715 | TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES. | $3.7M |
| Apr 13, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00056 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $1.3M |
| Sep 5, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93019C00056 | 541714 | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | $3.4M |
| Jun 29, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201500012C | 541711 | IGF::OT::IGF - OPTIMIZATION OF POLC POLYMERASE INHIBITORS FOR TREATMENT OF HIGH PRIORITY GRAM-POSITIVE PATHOGENS. | $82K |
| Sep 18, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201500012C | 541711 | IGF::OT::IGF - OPTIMIZATION OF POLC POLYMERASE INHIBITORS FOR TREATMENT OF HIGH PRIORITY GRAM-POSITIVE PATHOGENS. | $477K |
| Oct 23, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201500012C | 541711 | IGF::OT::IGF - OPTIMIZATION OF POLC POLYMERASE INHIBITORS FOR TREATMENT OF HIGH PRIORITY GRAM-POSITIVE PATHOGENS. | $1.8M |
| Feb 7, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201500012C | 541711 | IGF::OT::IGF - OPTIMIZATION OF POLC POLYMERASE INHIBITORS FOR TREATMENT OF HIGH PRIORITY GRAM-POSITIVE PATHOGENS. | $298K |
| Aug 24, 2016 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201500012C | 541711 | IGF::OT::IGF - OPTIMIZATION OF POLC POLYMERASE INHIBITORS FOR TREATMENT OF HIGH PRIORITY GRAM-POSITIVE PATHOGENS. | $1.5M |
Get Alerted Before Crestone, INC.'s Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start for free